Study #2018-0265
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
LHRH Analogue, Apalutamide, Abiraterone Acetate, Prednisone
Description
This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Prostate Cancer
Study phase:
Phase III
Physician name:
Paul Corn
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-866-599-0508
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.